Five patients developed a secondary leukemia (one AML-M3, one AML-MLL, one AML with RUNX1–CBFA2T3 fusion, one MDS-AML with CEPBA double mutation in blasts, one AML NOS). Here, RUNX1 is linked to myelodysplastic syndrome.